Literature DB >> 7615003

A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation.

D Graf1, S Müller, U Korthäuer, C van Kooten, C Weise, R A Kroczek.   

Abstract

TRAP is a tumor necrosis factor (TNF)-related, 33-kDa type II transmembrane protein almost exclusively expressed on the surface of activated CD4+ T lymphocytes. Interaction of TRAP with CD40 on B cells is of paramount importance for immunoglobulin class switching and subsequent synthesis of IgG, IgA or IgE in vivo. We now provide evidence that activated T cells not only express cell membrane-associated TRAP but also a soluble form of TRAP (sTRAP). After generating monoclonal antibodies against TRAP and establishing a TRAP-specific enzyme-linked immunosorbent assay we were able to detect substantial amounts of sTRAP in the supernatants of activated T cells. The onset and rate of sTRAP release was found to parallel the expression of TRAP on the cell surface. sTRAP, an 18-kDa protein, is generated by proteolytic processing of full-length TRAP in an intracellular compartment. Starting with methionine 113 of full-length TRAP, sTRAP lacks the transmembrane region and a part of the extracellular domain but contains the entire TNF-alpha homology region and can, therefore, bind to CD40. Like other members of the TNF superfamily (e.g. TNF-alpha, Fas/APO-1 ligand), TRAP thus has the potential to be biologically active not only in a transmembrane form but also as a soluble molecule.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615003     DOI: 10.1002/eji.1830250639

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  51 in total

Review 1.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction.

Authors:  Sonia Néron; Claudia Racine; Annie Roy; Matthieu Guérin
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

3.  Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation.

Authors:  Hyun-Jung An; Young Jin Kim; Dong Hyun Song; Beom Suk Park; Ho Min Kim; Ju Dong Lee; Sang-Gi Paik; Jie-Oh Lee; Hayyoung Lee
Journal:  J Biol Chem       Date:  2011-02-01       Impact factor: 5.157

Review 4.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  CD20, CD3, and CD40 ligand microclusters segregate three-dimensionally in vivo at B-cell-T-cell immunological synapses after viral immunity in primate brain.

Authors:  Carlos Barcia; Aurora Gomez; Vicente de Pablos; Emiliano Fernández-Villalba; Chunyan Liu; Kurt M Kroeger; Javier Martín; Andrés Fernández Barreiro; Maria G Castro; Pedro R Lowenstein; Maria-Trinidad Herrero
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

Review 6.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

8.  Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells.

Authors:  M J Martínez-Lorenzo; M A Alava; A Anel; A Piñeiro; J Naval
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

Review 9.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

10.  CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.

Authors:  Taha Elmetwali; Peter F Searle; Iain McNeish; Lawrence S Young; Daniel H Palmer
Journal:  Mol Cancer       Date:  2010-03-08       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.